CL2022000340A1 - Formulaciones anti-c5 de alta concentración. - Google Patents

Formulaciones anti-c5 de alta concentración.

Info

Publication number
CL2022000340A1
CL2022000340A1 CL2022000340A CL2022000340A CL2022000340A1 CL 2022000340 A1 CL2022000340 A1 CL 2022000340A1 CL 2022000340 A CL2022000340 A CL 2022000340A CL 2022000340 A CL2022000340 A CL 2022000340A CL 2022000340 A1 CL2022000340 A1 CL 2022000340A1
Authority
CL
Chile
Prior art keywords
formulations
high concentration
concentration anti
cemdisiran
ahus
Prior art date
Application number
CL2022000340A
Other languages
English (en)
Inventor
Mary Kleppe
Mayank Patel
Xiaolin Tang
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2022000340A1 publication Critical patent/CL2022000340A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente descripción incluye formulaciones farmacéuticas de alta concentración y baja viscosidad que incluyen un anticuerpo anti-C5 o su fragmento de unión a antígeno y arginina. Dichas formulaciones pueden proporcionarse en asociación con una molécula de ARNi como cemdisiran. También se proporcionan métodos para tratar enfermedades asociadas con C5 tales como HPN y SHUa.
CL2022000340A 2019-08-16 2022-02-09 Formulaciones anti-c5 de alta concentración. CL2022000340A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962888086P 2019-08-16 2019-08-16

Publications (1)

Publication Number Publication Date
CL2022000340A1 true CL2022000340A1 (es) 2022-10-07

Family

ID=72560889

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000340A CL2022000340A1 (es) 2019-08-16 2022-02-09 Formulaciones anti-c5 de alta concentración.

Country Status (14)

Country Link
US (1) US20210046182A1 (es)
EP (1) EP4013784A1 (es)
JP (1) JP2022544589A (es)
KR (1) KR20220047826A (es)
CN (1) CN116782876A (es)
AU (1) AU2020334880A1 (es)
BR (1) BR112022002831A2 (es)
CA (1) CA3145621A1 (es)
CL (1) CL2022000340A1 (es)
CO (1) CO2022001097A2 (es)
IL (1) IL290034A (es)
JO (1) JOP20220030A1 (es)
MX (1) MX2022001896A (es)
WO (1) WO2021034639A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3468990T3 (da) 2016-06-14 2024-06-24 Regeneron Pharmaceuticals Inc Anti-C5-antistoffer og anvendelser deraf
WO2023077053A2 (en) 2021-10-28 2023-05-04 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
WO2024026395A1 (en) * 2022-07-27 2024-02-01 Cephalon Llc Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease
WO2024026386A1 (en) * 2022-07-27 2024-02-01 Cephalon Llc Anti-tl1a antibody formulations
US20240175027A1 (en) * 2022-10-28 2024-05-30 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody/c5 irna co-formulations and combination therapies
CN116712390B (zh) * 2023-08-04 2023-11-14 上海览屹医药科技有限公司 一种高浓度高稳定性的抗体制剂及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
JP4656675B2 (ja) 1997-05-14 2011-03-23 ユニバーシティー オブ ブリティッシュ コロンビア 脂質小胞への荷電した治療剤の高率封入
WO2004007718A2 (en) 2002-07-10 2004-01-22 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rna-interference by single-stranded rna molecules
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
WO2007092772A2 (en) * 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
DK2279254T3 (en) 2008-04-15 2017-09-18 Protiva Biotherapeutics Inc PRESENT UNKNOWN LIPID FORMS FOR NUCLEIC ACID ADMINISTRATION
UA105009C2 (uk) 2008-08-05 2014-04-10 Новартіс Аг Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу
TR201811076T4 (tr) 2009-06-10 2018-08-27 Arbutus Biopharma Corp Geliştirilmiş lipit formulasyonu.
CA2904654C (en) 2013-03-14 2023-12-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
US10238700B2 (en) * 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
JP6718379B2 (ja) 2014-03-20 2020-07-08 インフラルクス ゲーエムベーハー ウイルス性肺炎治療のためのＣ５ａの阻害剤
EP3464351A1 (en) 2016-06-07 2019-04-10 Novartis AG Anti-c5 antibody for treating patients with complement c5 polymorphism
DK3468990T3 (da) * 2016-06-14 2024-06-24 Regeneron Pharmaceuticals Inc Anti-C5-antistoffer og anvendelser deraf
MA46466A (fr) * 2016-10-06 2019-08-14 Amgen Inc Formulations pharmaceutiques de protéines à viscosité réduite
DK3658184T3 (da) * 2017-07-27 2023-11-27 Alexion Pharma Inc Højkoncentrerede anti-c5-antistofformuleringer
MX2020004284A (es) * 2017-10-26 2020-10-28 Alexion Pharma Inc Dosis y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (hpn) y el sindrome hemolitico uremico atipico (shua).
JP2021506241A (ja) * 2017-12-13 2021-02-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｃ５抗体組み合わせ物およびその使用

Also Published As

Publication number Publication date
US20210046182A1 (en) 2021-02-18
MX2022001896A (es) 2022-06-02
WO2021034639A1 (en) 2021-02-25
CN116782876A (zh) 2023-09-19
EP4013784A1 (en) 2022-06-22
BR112022002831A2 (pt) 2022-06-28
CO2022001097A2 (es) 2022-03-08
JOP20220030A1 (ar) 2023-01-30
CA3145621A1 (en) 2021-02-25
KR20220047826A (ko) 2022-04-19
AU2020334880A1 (en) 2022-03-24
IL290034A (en) 2022-03-01
WO2021034639A4 (en) 2021-04-15
JP2022544589A (ja) 2022-10-19

Similar Documents

Publication Publication Date Title
CL2022000340A1 (es) Formulaciones anti-c5 de alta concentración.
DOP2020000128A (es) Anticuerpos anti-trem2 y métodos relacionados
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
ECSP18095014A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
ECSP20024555A (es) Anticuerpos especificos para cd47 y pd-l1
CL2018002694A1 (es) Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112)
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
CU20160101A7 (es) Inmunoglobulina con fab en tándem
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112017016952A2 (pt) terapia de combinação com fatores de coagulação e anticorpos multiespecíficos
UY34995A (es) Formulaciones de anticuerpo y proteína
CL2017000888A1 (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
BR112017016636A2 (pt) formulação líquida estável para anticorpos monoclonais
UY36194A (es) Anticuerpos anti-tau humanizados
BR112016014293A2 (pt) região de fragmento cristalizável canino, anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, e, método para aumentar a atividade de uma célula imune
CO2019002239A2 (es) Formulaciones, kits y métodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados
BR112017009807A2 (pt) métodos e formulações para tratamento de doenças oculares vasculares
CL2015000352A1 (es) Métodos de tratamiento de una tauopatía
BR112015021979A2 (pt) Anticorpos humanos para grem1
BR112015021134A2 (pt) conjugados de fármaco e anticorpo
CR20160319A (es) Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
BR112016014731A2 (pt) Anticorpos anti-baff